文献速递银屑病与炎症性皮肤病

生物制剂在临床实践中的比较有效性:国际观察性银屑病健康结局研究(PSoHO)第12周主要结局

Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-07-29

PSoHO是一项为期3年的国际观察性队列研究,纳入中重度斑块状银屑病成人患者,比较抗IL-17A生物制剂与其他获批生物制剂在第12周的有效性。抗IL-17A组71.4%达到PASI 90和/或sPGA 0/1,其他生物制剂组为58.6%(OR 1.9,95%CI 1.6-2.4),次要结局结果相似。

要点

  • 第12周抗IL-17A组71.4%达到PASI 90和/或sPGA 0/1,其他生物制剂组为58.6%(OR 1.9,95%CI 1.6-2.4)。
  • 抗IL-17A组患者银屑病关节炎合并症更常见,传统治疗暴露较少。
  • 作者结论认为结果反映IL-17A抑制剂的高疗效和早期起效,并证实其在真实世界中的有效性。

核心结论

  • 作者结论认为这些结果反映了随机临床试验中观察到的IL-17A抑制剂的高疗效和早期皮肤清除,并证实了抗IL-17A生物制剂在真实世界环境中的有效性。

研究设计与样本

  • PSoHO是一项正在进行的3年观察性队列研究,纳入患有慢性中重度斑块状银屑病、开始或换用新生物制剂的成人患者。
  • 主要研究终点为抗IL-17A队列(依奇珠单抗[IXE]、司库奇尤单抗)与所有其他获批生物制剂相比,第12周(W12)达到PASI 90和/或sPGA 0/1的患者比例。
  • 比较有效性分析采用频率模型平均(FMA)这一新的因果推断机器学习方法,二分类结局的缺失数据按无应答插补。

主要发现

  • 抗IL-17A队列与其他生物制剂队列的患者特征相似,但接受抗IL-17A生物制剂的患者合并银屑病关节炎更常见,传统治疗暴露较少。
  • 第12周时,接受抗IL-17A生物制剂的患者中71.4%达到PASI 90和/或sPGA 0/1,而接受其他生物制剂的患者为58.6%(OR 1.9,95%CI 1.6-2.4)。
  • 次要结局(包括PASI 75/90/100、绝对PASI评分≤5、≤2和≤1、DLQI评分0/1)也观察到相似的结果。

关键数值与推荐

  • 主要终点:第12周达到PASI 90和/或sPGA 0/1的患者比例,抗IL-17A组为71.4%,其他生物制剂组为58.6%(OR 1.9,95%CI 1.6-2.4)。
  • 次要结局包括第12周达到PASI 75/90/100、绝对PASI评分≤5、≤2和≤1、DLQI评分0/1的患者比例,结果与主要终点相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice. OBJECTIVES: To compare the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis. METHODS: The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year observational cohort study in adults with chronic moderate-to-severe plaque psoriasis initiating or switching to a new biologic. Primary study endpoint is the proportion of patients achieving 90% improvement in Psoriasis Area and Severity Index (PASI 90) and/or static Physician Global Assessment (sPGA) 0/1 at Week 12 (W12) in the anti-IL-17A cohort (ixekizumab [IXE], secukinumab) vs. all other approved biologics. Secondary outcomes include the proportion of patients who achieve PASI 75/90/100, absolute PASI scores ≤5, ≤2 and ≤1, Dermatology Life Quality Index (DLQI) score of 0/1 at W12 between the two cohorts and among the individual biologics. Comparative effectiveness analyses were conducted using Frequentist Model Averaging (FMA), a novel causal inference machine learning approach. Missing data for binary outcomes were imputed as non-response. RESULTS: Patient profiles in the anti-IL-17A cohort and other biologics cohort were similar, with more frequent comorbid psoriatic arthritis and less frequent exposure to conventional treatments in the patients receiving anti-IL-17A biologics. At W12, 71.4% of patients who received an anti-IL-17A biologic achieved PASI 90 and/or sPGA 0/1 compared to 58.6% of patients who received other biologics (odds ratios [OR], 1.9; 95% confidence intervals [CI], [1.6, 2.4]). Similar findings were observed for secondary outcomes. CONCLUSIONS: These results reflect the high efficacy and early onset of skin clearance of IL-17A inhibitors observed in randomized clinical trials and confirm the effectiveness of anti-IL-17A biologics in the real-world setting.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022. PMID: 35766124. doi:10.1111/jdv.18376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。